Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF V600 -mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

(2017) Max Schreuer et al.   LANCET ONCOLOGY

Treatment patterns of advanced malignant melanoma (stage III–IV) – A review of current standards in Europe

(2016) Mark Harries et al.   EUROPEAN JOURNAL OF CANCER

Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib

(2016) Heike Seifert et al.   MELANOMA RESEARCH

BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

(2016) Kristel Kemper et al.   Cell Reports

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

(2015) Gatien Moriceau et al.   CANCER CELL

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

(2015) K. Kemper et al.   EMBO Molecular Medicine

Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy

(2015) Claudia Wellbrock et al.   Pigment Cell & Melanoma Research

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

(2015) Rachel Ramsdale et al.   Science Signaling

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

(2015) Annelien Verfaillie et al.   Nature Communications

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment

(2015) Stefanie Riesenberg et al.   Nature Communications

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

(2015) Rachel Ramsdale et al.   Science Signaling

JUNB Is a Key Transcriptional Modulator of Macrophage Activation

(2014) Mary F. Fontana et al.   JOURNAL OF IMMUNOLOGY

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

(2014) Judith Müller et al.   Nature Communications

Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies

(2014) O. Abdel-Wahab et al.   Cancer Discovery

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series

(2014) Andrew J. Dooley et al.   Therapeutic Advances in Medical Oncology

Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia

(2013) Sascha Dietrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis

(2012) L. C. W. Vredeveld et al.   GENES & DEVELOPMENT

Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor

(2012) Amélie Clémentine Seghers et al.   MELANOMA RESEARCH

Conversion from the “oncogene addiction” to “drug addiction” by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation

(2011) Kenichi Suda et al.   LUNG CANCER

ERK2 but Not ERK1 Induces Epithelial-to-Mesenchymal Transformation via DEF Motif-Dependent Signaling Events

(2010) Sejeong Shin et al.   MOLECULAR CELL

Cancer stem cells versus phenotype-switching in melanoma

(2010) Keith S. Hoek et al.   Pigment Cell & Melanoma Research

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

(2008) K. S. Hoek et al.   CANCER RESEARCH